Research Areas

NCORP's research agenda is aimed at reducing cancer risk and incidence; improving cancer care outcomes; expanding access to cancer care; increasing quality and balancing cost; and reducing cancer disparities.

Clinical Trials

NCORP’s clinical trials research portfolio includes:

  • Cancer prevention studies to identify and evaluate interventions to reduce cancer risk and incidence;
  • Cancer control studies to reduce incidence and co-morbidity of cancer and its treatment, and enhance quality of life;
  • Cancer screening studies to evaluate early diagnosis interventions and cancer recurrence; and
  • Health-related quality of life or patient-reported outcomes research to identify secondary endpoints nested in the National Clinical Trials Network (NCTN) treatment trials.

Other research areas include:

  • Natural history and mechanisms of cancer and its treatment-related symptoms and toxicities;
  • Post-treatment surveillance (such as tumor markers of recurrence, and optimal screening modalities);
  • Under- and over-diagnosis of cancer; and
  • Management of pre-cancerous lesions.

Cancer Care Delivery Research (CCDR)

Cancer Care Delivery Research (CCDR) encompasses a multidisciplinary field of scientific investigation. It examines how social factors, financing systems, organizational structures and processes, health technologies, and healthcare provider and individual behaviors affect cancer outcomes, access to and quality of care, cancer care costs, and the health and well-being of cancer patients and survivors.

Cancer Disparities

Research questions in this area address disparities in clinical trial outcomes and cancer care delivery related to the most serious, prevalent cancers and cancer-related problems which disproportionately affect racial/ethnic minorities and underserved populations. It includes studies to: enhance participation of racial/ethnic minorities and the underserved in clinical trials; address determinants of disparities (for example, social and health care system factors, co-morbidities, and genomics); and evaluate differential outcomes in minority/underserved populations.